Brain Injuries
Conditions
Brief summary
Clinical pilot study to evaluate a new multi-parameter neuromonitoring device that allows the measurement of regional cerebral blood flow (rCBF), intracranial pressure (ICP), brain temperature monitoring and ventricular cerebrospinal fluid (CSF) drainage in brain-injured patients.
Interventions
DEVICEPlacement of the CBMS Probe
Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
Sponsors
Carag AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adult male or female patient, aged 18 - 75 years * Brain injured patients with acute intracranial hemorrhage (including aneurysmal subarachnoid hemorrhage (SAH) and spontaneous intracerebral hemorrhage (ICH)) who are admitted to the ICU and have an indication for ICP monitoring and CSF drainage, as per standard patient care * Informed consent obtained for research in emergency situations according to HRA art. 30 & 31 at time of inclusion
Exclusion criteria
* Known kidney disease, defined as plasma creatinine \> 120 μmol/l * Known liver disease, defined as AST \> 200 IU/L * Over-active thyroid or benign tumors of the thyroid * History of allergic disorders, including allergic reactions, against contrast agents containing iodine, or against ICG * Patients which have received one of the following medications before being admitted to ICU: Haloperidol, Meperidine, Methadone, Morphine, Phenobarbital and Rifamycin. * Patients with wounds or scars including the front orbital region. * Cerebrospinal fluid infection or signs of meningo-encephalitis * Anemia (hemoglobin \< 10 g/dl) or Thalassemia * Carbon monoxide poisoning * Acquired pathological or congenital disorders of the cerebral system, being clinically significant, respectively interfering in the investigator's opinion with the conduct of study * Documented history of bleeding, clotting or coagulation disorders * Patients who are not suitable for a CT perfusion * Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical investigation or will not comply with requirements of the study * Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation * Pre-existing disability and/or legal representative * Patients who are kept lawfully in an institution * Participation in another interventional clinical investigation within the last 30 days before start of treatment * History of, respectively diagnosis of pregnancy, or breastfeeding patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility: Comparability of regional CBF values and values obtained with CT perfusion and TCD | Up to 28 days until probe removal | Regional CBF values calculated with the investigational devices (CBMS) are within ranges described in literature, and dynamic changes of regional CBF are consistent to those values obtained with established methods CT perfusion and TCD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety related to catheter insertion and monitoring | Until 7 days after probe removal | Safety related to catheter insertion and monitoring: local hematomas, infections, CSF drainage dysfunction in comparison with other standard intra-ventricular devices. |
Countries
Switzerland
Outcome results
None listed